{
  "id": "644289c457b1c7a31500005e",
  "type": "list",
  "question": "Which are some symptoms of FSHD?",
  "ideal_answer": "The main symptoms of FSHD are facial weakness, proximal weakness of the upper limbs, lower limb weakness, truncal muscle weakness, periscapular weakness, foot dorsiflexor weakness, hip girdle weakness, and hearing loss. These symptoms are usually progressive and asymmetric.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/10864616",
    "http://www.ncbi.nlm.nih.gov/pubmed/14659411",
    "http://www.ncbi.nlm.nih.gov/pubmed/31409737",
    "http://www.ncbi.nlm.nih.gov/pubmed/11353419",
    "http://www.ncbi.nlm.nih.gov/pubmed/34675094",
    "http://www.ncbi.nlm.nih.gov/pubmed/11592052",
    "http://www.ncbi.nlm.nih.gov/pubmed/22907234",
    "http://www.ncbi.nlm.nih.gov/pubmed/15050443",
    "http://www.ncbi.nlm.nih.gov/pubmed/27530735",
    "http://www.ncbi.nlm.nih.gov/pubmed/32278354",
    "http://www.ncbi.nlm.nih.gov/pubmed/36030628",
    "http://www.ncbi.nlm.nih.gov/pubmed/22796148",
    "http://www.ncbi.nlm.nih.gov/pubmed/23785297",
    "http://www.ncbi.nlm.nih.gov/pubmed/32327287",
    "http://www.ncbi.nlm.nih.gov/pubmed/23225386",
    "http://www.ncbi.nlm.nih.gov/pubmed/32008231",
    "http://www.ncbi.nlm.nih.gov/pubmed/34964760",
    "http://www.ncbi.nlm.nih.gov/pubmed/23573589",
    "http://www.ncbi.nlm.nih.gov/pubmed/35020192",
    "http://www.ncbi.nlm.nih.gov/pubmed/33096728",
    "http://www.ncbi.nlm.nih.gov/pubmed/34559225",
    "http://www.ncbi.nlm.nih.gov/pubmed/12134683",
    "http://www.ncbi.nlm.nih.gov/pubmed/1908258",
    "http://www.ncbi.nlm.nih.gov/pubmed/31025273"
  ],
  "snippets": [
    {
      "text": "In most cases the condition initially presents with facial and proximal weakness of the upper limbs, but over the course of the disease involves lower limb and truncal muscles.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32327287",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Weakness is progressive and frequently asymmetric, which is a hallmark of the disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32327287",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "5 major FSHD symptoms: facial, periscapular, foot dorsiflexor, hip girdle weakness, and hearing loss.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32327287",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " patients with FSHD. Sponsors of treatments for FSHD patients should be aware of some of the common misconceptions associated with FSHD drug development with the goal of optimizing the chance to prove safety and efficacy for each potential treatment for FSHD in the clinical trial setting.RESULTS: Four major topics with potential clinical manifestations for patients with FSHD will be discussed related to muscle weakness, respiratory issues, animal models and prevalence.CONCLUSION: The authors offer multiple solutions to help counteract misconceptions with each scenar",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32008231",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here we performed an analysis of 643 FSHD1 patients in the UK FSHD patient registry, investigating factors affecting rate of onset of 5 major FSHD symptoms: facial, periscapular, foot dorsiflexor, hip girdle weakness, and hearing loss.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32327287",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "FAT1 lies near the critical locus involved in causing FSHD, and Fat1 mutant mice also show retinal vasculopathy, mimicking another symptom of FSHD, and showed abnormal inner ear patterning, predictive of deafness, reminiscent of another burden of FSHD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23785297",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RATIONALE: Early-onset facioscapulohumeral muscular dystrophy (FSHD) is defined as facial weakness before the age of 5 and shoulder weakness before the",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34964760",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A classical presentation (74%) and 3 facial sparing phenotypes: a mild presentation (5%) with later facial and periscapular involvement, an early shoulder presentation (10%) with accelerated periscapular weakness and an early foot presentation (9%) with accelerated foot dorsiflexor weakness.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32327287",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Patients with FSHD also had reduced systemic antioxidative response molecules, such as low levels of zinc (a SOD cofactor), selenium (a GPx cofactor involved in the elimination of lipid peroxides), and vitamin C. Half of them had a low ratio of gamma/alpha tocopherol and higher ferritin concentrations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22796148",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Facioscapulohumeral muscular dystrophy (FSHD) is characterized by progressive weakness and wasting of facial, shoulder-girdle and upper arm muscles.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15050443",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Typically, FSHD patients present with a recognizable constellation of signs including weakness of facial, shoulder and pelvic girdle, humeral, and anterior foreleg muscles; preservation of some muscles including the deltoids; and other characteristic features including prominent scapular winging, anterior axillary folds, and horizontally positioned clavicles.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11353419",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "physiology. Typically, progressive skeletal muscle weakness becomes noticeable in the second or third decade of life, yet there are many individuals who are genetically FSHD but develop symptoms much later in life or remain relatively asymptomatic throughout ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32278354",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "t neuromuscular disorder characterized by progressive weakness of the facial, shoulder and upper arm muscles. The major gene involved has been mapped ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11592052",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We report an 18-year-old female with facioscapulohumeral dystrophy (FSHD), who had sensorineural deafness, retinal vessel abnormality, mental retardation, and epilepsy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/1908258",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "cular dystrophy characterized by progressive weakness and wasting of the facial, shoulder-girdle and upper arm muscles. The gene locus for FSHD is map",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12134683",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "nherited myopathy clinically characterized by weakness in the facial, shoulder girdle and upper a muscles. FSHD is caused by chromatin relaxation of t",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34559225",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: Severe manifestations of facioscapulohumeral dystrophy (FSHD) may be associated with sleep-disordered breathing (SDB), including obstructive sleep apnea (OSA) and nocturnal hypoventilation (NH), but prevalence data are scarce",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31025273",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Consensual diagnostic criteria for facioscapulohumeral dystrophy (FSHD) include onset of the disease in facial or shoulder girdle muscles, facial weakness in more than 50% of affected family members, autosomal dominant inheritance in familial cases, and evidence of myopathic disease in at least one affected member without biopsy features specific to alternative diagnoses.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10864616",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "onset facioscapulohumeral muscular dystrophy (FSHD) present epilepsy and mental retardation. This suggests a functional involvement of central nervous",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/14659411",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " The major symptom of FSHD is progressive weakening and loss of skeletal muscles",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32008231",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "phy (FSHD) is an autosomal dominant disorder characterized by progressive muscle weakness. Adenine nucleotide translocator 1 (ANT1), the only 4q35 gen",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36030628",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "l symptoms are extremely variable including facial sparing type, limb-girdle type, and distal myopathy type. Most of the FSHD patients have a deletion",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15050443",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "facial weakness, facial dorsiflexor, proximal weakness of the upper limbs, periscapular dorsiflexor, lower limb weakness, hip girdle weakness, foot dorsiflexor, truncal muscles weakness, asymmetric weakness, hearing loss."
}